Cardioxyl Pharmaceuticals competitors

Dr. Tabuteau has served as our founder, Chief Executive Officer, and Chairman of our board of directors since our founding in January 2012. Prior to founding our company, Dr. Tabuteau was a Senior Analyst and Partner at Healthco/S.A.C. Capital (now known as HealthCor) where he was responsible for the biotechnology, genomics, and instrumentation portfolios. Previously, Dr. Tabuteau was the healthcare analyst at Kingdon Capital. Prior to that position, Dr. Tabuteau was a Senior Research Analyst at Banc of America Securities covering the hospital supplies sector. Prior to Banc of America, Dr. Tabuteau was part of the healthcare investment banking group at Goldman Sachs. Dr. Tabuteau earned his M.D. from Yale University School of Medicine and his Bachelor of Arts in molecular biology and biochemistry from Wesleyan University.

David Cory is an entrepreneur and industry veteran with 25-years experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational, transactional, and financial success.Mr. Cory is currently the President and CEO of Eiger BioPharmaceuticals since 2008. He is responsible for negotiating Eiger’s multiple product licenses from Merck and Astra Zeneca. Cory was previously President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail Pharmaceuticals for $160 million in 2008. Cory was Co-Founder and Chief Commercial Officer at CoTherix, an Orphan Pulmonary Hypertension company, which was acquired by Actelion for $425 million in 2006. Cory began his start up career as Senior Vice President of Commercial Operations at InterMune, a public biotechnology company focused on developing Orphan products for Idiopathic Pulmonary Fibrosis. He was as a key executive in the InterMune IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. Mr. Cory spent the first 12 years of his career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline leading teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, where he directed 10 pharmaceutical product launches and the commercialization of 20 brands.David Cory is a graduate of the University of Cincinnati, College of Pharmacy, is board certified in Pharmacy, and holds a Masters Degree in Business Administration from the University of Maryland.

Ms. Anna Protopapas is a Chief Executive Officer at MERSANA THERAPEUTICS, INC. and is based in United States.

President, Chief Executive Officer and Director of SCYNEXIS Inc. (Nasdaq: SCYX) and Director of various public companies and non-profit organizationsCompleted several successful rounds of financing and company restructuringExperience as a Director in Boards of public companies (Audit Committee, Compensation Committee and Governance & Nominating Committee) Managed groups up to 1,600 employees in global organizations and R&D budgets up to $950MM/yearOver 35 products approved through various regulatory paths [505(b)1, 505(b)2, 510(k) devices and ANDA] in the US and globally in Europe and South America:Anti-Infectives: Cedax (ceftibuten, Global), Isepacin (isepamicina - Europe), Cleeravue-M (minocycline for skin infections - US), Teflaro (ceftaroline - US), Colobreathe (Inhaled Colistin for cystic fibrosis - Europe), Avycaz (Ceftazidime/Avibactam)Oncology: Intro-A (Interferon-α in Non-Hodgkin lymphoma - US), Fareston (toremifene for breast cancer -US), Temodar (Temozolomide for brain tumors- Global) Central Nervous System: Subutex (buprenorphine for opioid addictions, Global), Savella (milnacipran for fibromyalgia - US), Lexapro pediatric (escitalopram - US), Namenda XR (memantine for Alzheimer disease, US), Fetzima (levomilnacipran for Major Depression Disorder - Global) Cardiovascular: Bystolic (nebivolol for hypertension - US)Gastroenterology: Linzess (linaclotide for IBSc and CIC - US)Respiratory Medicine: Daliresp (roflumilast for COPD - US), Tudorza (Aclidinium for COPD - US)Dermatology: Lotrisone Lotion (US for eczema), Mometasone Pediatric (US), MimyX (US), Duac (Global), Ciclopirox Shampoo (Global), Ciclopirox solution (Global), Rosac Wash (US), Brevoxyl Pads (US), Levulan (Global)Generics (US): Griseofulvin Suspension, Sodium Sulfacetamide Wash, Urea CreamOTC/Cosmeceuticals: Physiogel sunscreen (International), PanOxyl 10%, Foaming Acne Wash, Clariderm (International), Mimyx (US), SunMAX line (International), LactiCare HC (International)

• Member of the National Ernst and Young Entrepreneur of the Year Hall of Fame• Inducted into the University of Texas College of Natural Sciences Hall of Honor• Received Ohio University's School of Business Distinguished Business Award• Received Ohio University Konneker Medal, the highest award given to a faculty member or former student for entrepreneurial excellence• Named one of the top 10 Life Sciences CEOs in Texas by the Texas Healthcare and Bioscience InstituteMr. Hawkins is currently the President and CEO of Lumos Pharma, Inc. an early-stage orphan drug company based in Austin, Texas. He currently serves as a Board of Director for SciClone Pharmaceuticals Inc., a NASDAQ listed company (SCLN), a biopharmaceutical company whose lead product Zadaxin, an adjuvant for the influenza vaccine in immunocompromised patients or as an immune stimulant, has been approved in at least 13 countries.In addition he serves as a Board of Director for Cytori Therapeutics, Inc.; a global leader in stem cell research and the use of adipose derived stem and regenerative cells.Rick Hawkins is a member of the National Ernst and Young Entrepreneur of the Year Hall of Fame.Mr. Hawkins was inducted into the Hall of Honor for the College of Natural Sciences at the University of Texas by Dean, Mary Ann Rankin. In 2006 he received Ohio University’s Distinguished Business Achievement Award, and in 2014 was awarded the Konneker Medal, the leading entrepreneurial honor awarded by the University. Rick was named one the top 10 Life Sciences CEO’s in Texas by the Texas Healthcare & Bioscience Institute and was the keynote speaker at BioVenture Showcase 2008.

James Fairbairn has 20+ years in senior finance roles with emerging companies. He is a Chartered Professional Accountant, having obtained his CPA designation in 1987 and is an Institute-certified Director. Jim holds a Bachelor of Arts from the University of Western Ontario. He is a director of several junior listed companies.